Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...
The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring. | The company is working with regulators to ensure stable ongoing supply for the one-time gene therapy ...
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...
The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more ...
Stockhead on MSN
Dr Boreham’s Crucible: CSL’s tough diagnosis
A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...
I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results